Changes And Their Significance Of CD62P,CD63 And PAF In Deep Venous Thrombosis Of Lower Limbs Patients

Research?Background Deep venous thrombosis of lower limbs(LDVT)is a common peripheral vascular disease. It's incidence in peripheral vascular disease is about 40%, with a tendency of growing every year, which making it now a most common disease to harm people's health. A rudiment assessment said that there were about 30,000,000 deep venous thrombosis of lower limbs and their sequel patients at present in China. If the patient is not diagnosed ang treated at the acute stage of deep venous thrombosis of lower limbs, they may accompany pulmonary embolism because of the thrombus ablation. Correlated literatures reported that there were about 100,000 people died of pulmonary embolism. Besides, most of the patients who were not treated in time can not avoid the occurrence of deep venous thrombosis of lower limbs sequel, having a long term pain, affecting their living and working ability, some even mutilated. So it is very important to study the early diagnosis and treatment in our clinic work.Objective To investigate the differences of Platelet CD62P, CD63 and PAF in deep venous thrombosis of lower limbs patients and healthy people.Method Selected LDVT patients and healthy people. LDVT patients were grouped into Ozagrel treatment group and normal treatment group by their sequence of admission to hospotial. To draw the blood of LDVT patients and healthy people before treatment, 6 days and 10 days after treatment respectively. The positive expressing rate of CD62P and CD63 were examined by monoclonal antibodies using flow cytometer; the content of PAF were detected by double antibody sandwich method using enzyme-linked immunosorbent test. The changes of CD62P and CD63 positive expressing rate, PAF content and the medicine availability were observed at different time after medicine interference.Results (1)CD62P and CD63 positive expressing rate and PAF content in LDVT group was obviously higher than the control group(P<0.05); (2)CD62Pand CD63 positive expressing rate and PAF content showed decline tedency after treated by Ozagrel. (3)There were significant differences of CD62P and CD63 positive expressing rate between Ozagrel treatment group and normal treatment group, while there were no significant differences of PAF content between the two groups. (4)10 days after treatment, there were no significant differences of CD62P positive expressing rate between Ozagrel treatment group and healthy people, but CD63 positive expressing rate and PAF content in Ozagrel treatment group were still higher than healthy people; CD62P and CD63 positive expressing rate and PAF content in normal treatment group are higher than healthy peopleConclusion Platelet were activated and fibrinolysis were accentuated at the early stage of LDVT. Ozagrel could decline the platelet activation. Dectecting the changes of CD62P , CD63 and PAF in LDVT patients'blood will provide a now method for the targeted therapy of LDVT. LDVT patients discharged from hospital are still the high risk group of thrombosis, so should be followed up regularly.